Remote video URL
Your peers have not rated this talk yet.
10-minute watch | Talk 15 of 15

ASCO, EHA & ICML: Expert perspective

Brexucabtagene autoleucel in R/R B‑cell acute lymphoblastic leukaemia: Real‑world data

Dr Bijal Shah
Moffitt Cancer Center, Tampa, FL, USA

Dr Bijal Shah, from the Moffitt Cancer Center, Florida, USA, summarises real-world outcomes with brexucabtagene autoleucel in acute lymphoblastic leukaemia, released during the 2023 summer congress season

Read more

Talks in this series

4-minute watch | Talk 1 of 15
ASCO, EHA & ICML: Expert perspective
4-minute watch
ASCO, EHA & ICML: Expert perspective

Updates on front‑line management in NHL

4-minute watch | Talk 1 of 15
ASCO, EHA & ICML: Expert perspective
4-minute watch
ASCO, EHA & ICML: Expert perspective

Updates on front‑line management in NHL

Interested in this topic?

Suggested for you

Explore suggested content tailored to your role within the CAR T-cell therapy journey

Job code: IHQ-UNB-4903 Date of preparation: October 2023
Job code: IHQ-UNB-4971 Date of preparation: October 2023

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.

Reporting of side effects 
If you get any side effects, talk to your doctor or nurse. In Great Britain and Northern Ireland, you can also report side effects directly via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. You can also report side effects and quality complaints to Gilead. For information now how to report a side effect in another country, click here. By reporting side effects, you can help provide more information on the safety of this medicine.